pirenzepine has been researched along with Colitis in 3 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carbachol-induced contraction of the rat colon is impaired in rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis." | 7.77 | Colonic inflammation increases the contribution of muscarinic M2 receptors to carbachol-induced contraction of the rat colon. ( Jragh, DM; Khan, I; Oriowo, MA, 2011) |
| "Pirenzepine has been widely used for the treatment of gastric and duodenal ulcer." | 5.27 | Pirenzepine as anti-inflammatory drug in a model of experimental colitis in rat. ( Bustos-Fernández, L; Celener, D; González, E; Hamamura, S; Kofoed, JA; Ledesma de Paolo, MI; Schiffrin, E, 1987) |
| "Carbachol-induced contraction of the rat colon is impaired in rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis." | 3.77 | Colonic inflammation increases the contribution of muscarinic M2 receptors to carbachol-induced contraction of the rat colon. ( Jragh, DM; Khan, I; Oriowo, MA, 2011) |
| "Pirenzepine has been widely used for the treatment of gastric and duodenal ulcer." | 1.27 | Pirenzepine as anti-inflammatory drug in a model of experimental colitis in rat. ( Bustos-Fernández, L; Celener, D; González, E; Hamamura, S; Kofoed, JA; Ledesma de Paolo, MI; Schiffrin, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jragh, DM | 1 |
| Khan, I | 1 |
| Oriowo, MA | 1 |
| Hirota, CL | 1 |
| McKay, DM | 1 |
| Bustos-Fernández, L | 1 |
| González, E | 1 |
| Kofoed, JA | 1 |
| Hamamura, S | 1 |
| Schiffrin, E | 1 |
| Celener, D | 1 |
| Ledesma de Paolo, MI | 1 |
3 other studies available for pirenzepine and Colitis
| Article | Year |
|---|---|
Colonic inflammation increases the contribution of muscarinic M2 receptors to carbachol-induced contraction of the rat colon.
Topics: Animals; Carbachol; Colitis; Colon; Diamines; Disease Models, Animal; Inflammation; Isometric Contra | 2011 |
M3 muscarinic receptor-deficient mice retain bethanechol-mediated intestinal ion transport and are more sensitive to colitis.
Topics: Animals; Bethanechol; Cholinergic Fibers; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; I | 2006 |
Pirenzepine as anti-inflammatory drug in a model of experimental colitis in rat.
Topics: Acetates; Acetic Acid; Animals; Colitis; Colon; Colonic Diseases; Edema; Male; Mucus; Pirenzepine; R | 1987 |